Evaluation of tumor markers in Southern Indian breast cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 1, 2010, Pages 157-159

  Porika, Mahendar ^a   Malotu, Nagulu ^a   Veldandi, Uday Kiran ^a   Yadala, Nalini ^b   Abbagani, Sadanandam ^a  

^a KAKATIYA UNIVERSITY   (India)

^b Department of Paediatrics   (India)

Author keywords

Breast cancer; Cancer antigen; Carcinoembryonic antigen; Diagnosis; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MUCIN 1; TUMOR MARKER;

ADULT; AGED; BLOOD; BREAST; BREAST NEOPLASMS; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; EVALUATION STUDY; FEMALE; HUMAN; INDIA; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; FEMALE; HUMANS; INDIA; LYMPHATIC METASTASIS; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77955829955     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Arsalan N, Serdar M, Deveci S, et al, (2000). Use of CA I5-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis. Ann Nucl Med, 14, 395-9.
2. Bland KI, Beenken SW, Copeland EM, (2005). The breast. In: Bruniardi FC, Anderson DK, Billjar TR, et al (eds): Schwartz Principles of Surgery Eight edition, 453-96.
3. Fiorella G, Patrizia F, Sandro C, et al, (2001). A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res, 7, 2357-62.
4. James TWU, (2001). Diagnosis and management of cancer using serologic tumor markers. In: Henry JB, ed. Clinical Diagnosis and Management by Laboratory Methods. 20th ed. New York: WB Saunders, 1028-1042.
5. Lumachi F, Brandes AA, Ermani M, Bruno G, Boccagni P, (2000). Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res, 20, 4751-5.
6. Mahindocht K, Soheila N, Ardeshir D, (2005). Serum CA15-3 measurement in breast cancer patients before and after mastectomy. Arch Iranian Med, 8, 263-6.
7. Malati T, (2007). Tumor markers: an overview. Indian J Clinical Biochem, 22, 17-31.
8. Miya T, Watanabe T, Adachi I, et al, (1992). Analysis of cytosol CA15-3, carcinoembryonic antigen, and estrogen and progesterone receptors in breast cancer tissues. Jpn J Cancer Res, 83, 171-7.
9. Molina R, Jo J, Filella X, et al, (1998). C-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat, 51, 109-19.
10. Muthuswamy S, Raste AS, (2000). Clinical significance of cancer antigen, CA 15.3 in breast cancer. Indian J Med Sci, 54, 442-7.
11. Park BW, Oh JW, Kim KS, et al, (2008). Preoperative CA 15.3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol, 19, 675-681.
12. Roisman I, Israeli A. Lifshitz I, et al, (1994). The significance of the CA 15-3 breast tumuor marker as an addi-tional tool for detection of breast cancer. J Tumor Marker Oncol, 9, 19-24.
13. Saphner T, Turmey DC, Gray R, (1996). Annual hazard rate of recurrence for breast cancer after primery therapy. J Clin Oncol, 14, 2738.
14. Sikorska H, Shuster J, Gold P, (1988). Clinical applications of carcinoembryonic antigen. Cancer Detect Prevent, 12, 321-55.
15. Vizacarra E, Lluch A, Cibrian R, et al, (1996). Value of Ca15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease free follow-up patients and sensitivity in patients at diagnosis of first metastasis. Breast Cancer Res Treat, 37, 209-206.
16. Winer EP, Morro WM, Kent OC, Harries JR, (2001). Malignant tumors of the breast. In: Vincent Devita T., Jr. Samuel Hellman, Steven A. Rosenberg. Cancer Principles and Practice of Oncology 6th Edition, 2:1651, 1698-9.